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Two years ago, when biologists
declared victory in sequencing
the human genome, the
announcement seemed all the
more believable because the
president of the United States
himself was there to share the
glory. Two years later, cancer has
still not been cured, the major
genetic causes of diabetes have
not been uncovered, and truth be
told, the human genome has still
not really been fully sequenced.
So perhaps it’s not such a
surprise that when some of the
same cast of characters
assembled once again to
announce a project that could
possibly make all that genomic
information clinically relevant,
there were no blinding lights, no
banks of television cameras, no
Secret Service security checks,
and no Page One headlines.
The announcement in question
took place in Washington on 29
October. Like the genome project,
it involved scientists around the
world — US, England, Japan,
China and Canada — and
commercial enterprises as well.
The challenge they are taking on
is to create a haplotype map, or
hapmap, to catalog the common
variants in the human genome.
The project could have ‘a
profound impact on the future of
medicine,’ reported the
Washington Post, quoting Francis
Collins, director of the National
Human Genome Research
Institute. ‘[Collins said] it was an
essential next step in turning the
promise of the Human Genome
Project into concrete health
information.’
The hope (and hype?) springs
from an observation, less than
two years ago, that there are
perhaps just 200,000 segments of
DNA that reshuffle in the course
of human reproduction. Each
segment comes in a small number
of varieties (haplotypes), maybe 4
or 5. Even though the number of
possible recombinations is still a
mighty number —200,000 to the
4th or 5th power — it’s not nearly
as staggering as trying to
understand human variations by
looking at possible
recombinations for all 3 billion
base-pairs of DNA, or even the
10 million or so single nucleotide
polymorphisms (SNPs) thought to
be lurking in the genome.
But the promise is so uncertain,
journalists don’t know what to
make of it. The Houston Chronicle
decided to play it safe by playing
up the local angle: ‘With a
blueprint of the human genome all
but complete, Baylor College of
Medicine scientists have joined
an international team of
researchers who will now map the
genetic variations contributing to
humanity’s most common
illnesses, including heart disease
and cancer.’
The Wall Street Journal’s story,
on page D-4, focused on the nuts-
and-bolts of the project — how
much it would cost, who’s
involved, and which companies
have a hand in it. The report
repeated the claims of Collins and
others without much conviction.
And the New York Times ‘went
negative,’ as US political
strategists might put it. The Times
dutifully reported the
announcement, but then let the
critics pile it on. ‘I have some
major reservations,’ said Dr.
Kenneth Kidd, a population
geneticist at Yale. Dr. Kenneth
Weiss, a population geneticist at
Pennsylvania State University,
said he was, ‘skeptical about the
chance the hapmap will satisfy
the objectives of identifying
common major disease variants.’
And Dr. Kari Stefansson, chief
executive of Decode Genetics of
Reykjavik, Iceland, said he
thought the hapmap ‘would be an
inefficient way of finding disease
genes.’
The nub of the criticism (other
than scientists like Stefansson
believing that their own methods
are superior) is that the success
of the hapmap depends on a
largely untested idea: that
common diseases share common
genetic variants. The hope is that
perhaps a dozen genes inherited
together underlie the majority of
common maladies such as
hypertension, diabetes and
schizophrenia.
One of the chief proponents of
this idea is Eric Lander at MIT’s
Whitehead Institute. Lander was
absent, for once, from the press
conference. But Fortune
magazine seized the opportunity
to run a long and complimentary
profile. 
Lander speaks with
unstoppable optimism about the
power of the hapmap, predicting
a ‘huge explosion’ of gene
discoveries around mid-decade.
It’s hard to bet against a man
who’s proven himself smarter
than just about anybody else but
it’s also hard to swallow whole
the idea that the hapmap is the
pot of gold at the end of the
genomics rainbow. Lander himself
handles this issue with skill that
would impress the most hardened
politician. He blames the media
and pours fuel on the fire at the
same time. He told Fortune that,
‘the media may be overhyping
genes,’ and then a few breaths
later, adds, ‘Of course, it’s nuts to
say we’re going to understand the
genetic basis of all diseases in a
time span relevant to Wall Street.
But it’s equally nuts to imagine
that we won’t over the next 30 to
40 years.’
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Mediawatch: Richard F. Harris contrasts the media’s response two
years ago to the announcement of the sequencing of the human
genome sequence with the new haplotype mapping project to
determine genetic links to common diseases.
